Trial reportNeurologia medico-chirurgica2021
A Prospective Randomized Study on the Preventive Effect of Japanese Herbal Kampo Medicine Goreisan for Recurrence of Chronic Subdural Hematoma.
Trial report in Neurologia medico-chirurgica, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05713630 (TRACE STUDY), which is not on this map. Cited by 16 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
TRACE STUDY: A Randomized Controlled Trial Using Tranexamic Acid in the Treatment of Subdural Hematoma
Who cites it
16 citing papers in PubMed, 6 syntheses or guidelines pooled it, 31 citations in OpenAlex.
- Updated systematic review of current randomised controlled trials in chronic subdural haematoma.Acta neurochirurgica · 2025Pooled it
- Effectiveness of traditional herbal Kampo medicine Goreisan on chronic subdural hematoma recurrence: a meta-analysis.Frontiers in pharmacology · 2024Pooled it
- Anti-Inflammatory Drug Therapy in Chronic Subdural Hematoma: A Systematic Review and Meta-Analysis of Prospective Randomized, Double-Blind and Placebo-Controlled Trials.International journal of molecular sciences · 2022Pooled it
- Effectiveness Comparisons of Drug Therapy on Chronic Subdural Hematoma Recurrence: A Bayesian Network Meta-Analysis and Systematic Review.Frontiers in pharmacology · 2022Pooled it
- Pharmacological Treatment in the Management of Chronic Subdural Hematoma.Frontiers in aging neuroscience · 2021Pooled it
- From burr-hole to embolization: unveiling the evolution of chronic subdural hematoma research (2001-2025).Frontiers in neurologyPooled it
- Effect of postoperative tranexamic acid on recurrence rate and complications in chronic subdural hematomas patients: preliminary results of a randomized controlled clinical trial.Neurosurgical review · 2023Trial
- Management of chronic subdural hematoma: a consensus statement from the 2024 Copenhagen joint iCORIC/DACSUHS symposium.Acta neurochirurgica · 2026Review
- Article
- Effects of Goreisan in the Perioperative Period of Subthalamic Deep Brain Stimulation in Parkinson's Disease.Brain and behavior · 2024Article
- Herbal medicine Oryeongsan (Wulingsan): Cardio-renal effects via modulation of renin-angiotensin system and atrial natriuretic peptide system.Integrative medicine research · 2024Review
- Time-of-flight magnetic resonance angiography for detection of postoperative recurrence in patients with chronic subdural hematoma.Acta neurologica Belgica · 2023Article
- Impact of Goreisan components on rat mesenteric collecting lymphatic vessel pumping.Microcirculation (New York, N.Y. : 1994) · 2023Article
- Article
- Endoscopically observed outer membrane of chronic subdural hematoma after endovascular embolization of middle meningeal artery.Surgical neurology international · 2022Article
- Japanese herbalSurgical neurology international · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although the recurrence of chronic subdural hematoma (CSDH) after surgical treatment significantly affects the patients' quality of life, the recurrence rate has not improved in decades. Goreisan, a Japanese herbal Kampo medicine, promotes the hydragogue effect and has been empirically used in the treatment of CSDH in Japan. We conducted a prospective randomized study to investigate whether Goreisan treatment decreases the recurrence rate of CSDH. Between March 2013 and December 2018, a total of 224 patients who underwent initial burr hole surgery for CSDH were randomly assigned to receive Goreisan for 3 months (Group G) or no medication (Group N). The primary endpoint was symptomatic recurrence within 3 months postoperatively, and the secondary endpoint was complications, including the adverse effects of Goreisan. Of 224 randomized patients, 208 were included in the final analysis (104 in Group G and 104 in Group N). The overall recurrence rate was 9.1% (19/208). The recurrence rate of Group G was lower than that of Group N (5.8% vs 12.5%, P = 0.09), but the difference was not statistically significant. However, a significant preventive effect of Goreisan was found in 145 patients with high-risk computed tomography (CT) features, namely, homogeneous and separated types (5.6% vs 17.6%, P = 0.04). Although the present study did not prove the beneficial effect of Goreisan treatment, it suggested the importance of selecting patients with an increased risk of recurrence. A subset of patients whose hematoma showed homogeneous and separated patterns on CT image might benefit from Goreisan treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.